Cannabigerol (CBG)

Cannabigerol, or CBG, was discovered in 1964 by Yehiel Gaoni and Raphael Mechoulam in Israel and has shown a wide range of medicinal efficacy. This includes research indicating that it may be effective in the treatment of bladder dysfunction, cancer in general, colon cancer specifically, glaucoma, Huntington disease, immune dysfunction, multiple sclerosis, and inflammatory bowel disease.

Copyright © Higher Learning LV™

A 2019 study entitled "Could the Combination of Two Non-Psychotropic Cannabinoids Counteract Neuroinflammation Effectiveness of Cannabidiol Associated with Cannabigerol" that was published in the journal Medicina explored the ability of CBD and CBG, used in combination, to treat neuroinflammation and, thus, be part of an effective therapy against neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).

Stated the report, "In this study, we investigate the anti-inflammatory, antioxidant, and antiapoptotic properties of two non-psychoactive phytocannabinoids, cannabigerol (CBG) and cannabidiol (CBD)."

The study concluded that a combination of CBD and CBG possesses "anti-inflammatory, antioxidant, and antiapoptotic" properties and might be effective in the treatment of neurological diseases such as ALS. "Our results provide preliminary support on the potential therapeutic application of a CBG-CBD combination for further preclinical studies."

A 2018 study entitled "In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid" that was published in the International Journal of Molecular Sciences explored the role of inflammation and oxidative stress in neurodegeneration and how CBG might act as a preventative agent to reduce or eliminate this loss of healthy neurons in the brain and CNS.

Reported the researchers, "[Hemp] represents a reservoir of compounds exerting beneficial properties, including cannabigerol, whose antioxidant properties have already been demonstrated." The researchers reported that "CBG pre-treatment counteracted not only inflammation, but also oxidative stress."

"All together, these results indicated the neuroprotective effects of CBG, that may be a potential treatment against neuroinflammation and oxidative stress," concluded the study's authors.